Lineage Cell Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LCTX research report →
Companywww.lineagecell.com
Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
- CEO
- Brian Culley
- IPO
- 1992
- Employees
- 70
- HQ
- Carlsbad, CA, US
Price Chart
Valuation
- Market Cap
- $326.58M
- P/E
- -5.00
- P/S
- 22.10
- P/B
- 5.96
- EV/EBITDA
- -6.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 97.98%
- Op Margin
- -255.14%
- Net Margin
- -434.44%
- ROE
- -152.10%
- ROIC
- -34.07%
Growth & Income
- Revenue
- $14.56M · 53.24%
- Net Income
- $-63,533,000 · -241.41%
- EPS
- $-0.28 · -201.08%
- Op Income
- $-21,779,000
- FCF YoY
- 17.82%
Performance & Tape
- 52W High
- $2.09
- 52W Low
- $0.48
- 50D MA
- $1.51
- 200D MA
- $1.58
- Beta
- 1.60
- Avg Volume
- 1.38M
Get TickerSpark's AI analysis on LCTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 12, 26 | Culley Brian M | buy | 15,000 |
| Mar 5, 26 | Culley Brian M | other | 3,250,000 |
| Mar 5, 26 | Howe Jill Ann | other | 1,050,000 |
| Mar 5, 26 | Samuel George A. III | other | 900,000 |
| Feb 11, 26 | Culley Brian M | other | 31,250 |
| Feb 11, 26 | Culley Brian M | other | 12,869 |
| Feb 11, 26 | Culley Brian M | other | 31,250 |
| Feb 11, 26 | Samuel George A. III | other | 6,075 |
| Feb 11, 26 | Samuel George A. III | other | 2,502 |
| Feb 11, 26 | Samuel George A. III | other | 6,075 |
Our LCTX Coverage
We haven't published any research on LCTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LCTX Report →